MiR-144 Functions As a Tumor Suppressor in Breast Cancer Through Inhibiting ZEB1/2-mediated Epithelial Mesenchymal Transition Process

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2016 Oct 28

PMID 27785072

Citations 35

Authors

Yuliang Pan

Jun Zhang

Huiqun Fu

Liangfang Shen

Affiliations

Soon will be listed here.

Abstract

Breast cancer is the most common cancer in women worldwide. Local invasion, metastasis, and chemotherapy resistance are the obstacles for treatment of breast cancer. In this study, we aim to investigate the role of miR-144 in breast cancer. We demonstrate that the expression of miR-144 is downregulated in breast cancer and cell lines, and lower miR-144 expression is associated with poor differentiation, higher clinical stage, and lymph node metastasis in patients with breast cancer. The rescue of miR-144 expression is able to inhibit the cell proliferation and the ability of cell migration and invasion. In addition, we show that miR-144 can directly target at 3'-untranslation region of zinc finger E-box-binding homeobox 1 and 2, that is, ZEB1 and ZEB2, and regulate their expression at transcriptional and translational levels. Moreover, we also demonstrate that ectopic expression of miR-144 can inhibit the process of epithelial mesenchymal transition in MCF-7 and MDA-MB-231 cells. Thus, we here demonstrate that miR-144 functions as a tumor suppressor in breast cancer at least partly through inhibiting ZEB1/2-mediated epithelial mesenchymal transition process. Our findings indicate that the miR-144-ZEB1/2 signaling could represent a promising therapeutic target for breast cancer treatment.

Citing Articles

Bioinformatic and experimental analyses of GATA3 and its regulatory miRNAs in breast Cancer.

Roohy F, Moghanibashi M, Tahmasebi S Discov Oncol. 2024; 15(1):588.

PMID: 39448444 PMC: 11502614. DOI: 10.1007/s12672-024-01479-y.

MicroRNA, mRNA, and Proteomics Biomarkers and Therapeutic Targets for Improving Lung Cancer Treatment Outcomes.

Ye Q, Raese R, Luo D, Cao S, Wan Y, Qian Y Cancers (Basel). 2023; 15(8).

PMID: 37190222 PMC: 10137184. DOI: 10.3390/cancers15082294.

Zeb2 DNA-Binding Sites in Neuroprogenitor Cells Reveal Autoregulation and Affirm Neurodevelopmental Defects, Including in Mowat-Wilson Syndrome.

Birkhoff J, Korporaal A, Brouwer R, Nowosad K, Milazzo C, Mouratidou L Genes (Basel). 2023; 14(3).

PMID: 36980900 PMC: 10048071. DOI: 10.3390/genes14030629.

Circulating miRNA Expression Profiling in Breast Cancer Molecular Subtypes: Applying Machine Learning Analysis in Bioinformatics.

Triantafyllou A, Dovrolis N, Zografos E, Theodoropoulos C, Zografos G, Michalopoulos N Cancer Diagn Progn. 2022; 2(6):739-749.

PMID: 36340453 PMC: 9628143. DOI: 10.21873/cdp.10169.

Identification of the hub genes and transcription factor-miRNA axes involved in -associated gastric cancer.

Zhao P, Ma X, Cheng J, Chen H, Li L Oncol Lett. 2022; 23(3):89.

PMID: 35126731 PMC: 8805177. DOI: 10.3892/ol.2022.13209.

References

Sureban S, May R, Lightfoot S, Hoskins A, Lerner M, Brackett D . DCAMKL-1 regulates epithelial-mesenchymal transition in human pancreatic cells through a miR-200a-dependent mechanism. Cancer Res. 2011; 71(6):2328-38. PMC: 3072762. DOI: 10.1158/0008-5472.CAN-10-2738. View

Jabbarzadeh Kaboli P, Rahmat A, Ismail P, Ling K . MicroRNA-based therapy and breast cancer: A comprehensive review of novel therapeutic strategies from diagnosis to treatment. Pharmacol Res. 2015; 97:104-21. DOI: 10.1016/j.phrs.2015.04.015. View

Fedele P, Orlando L, Schiavone P, Calvani N, Caliolo C, Quaranta A . Recent advances in the treatment of hormone receptor positive HER2 negative metastatic breast cancer. Crit Rev Oncol Hematol. 2015; 94(3):291-301. DOI: 10.1016/j.critrevonc.2015.01.001. View

Rhodes L, Martin E, Segar H, Miller D, Buechlein A, Rusch D . Dual regulation by microRNA-200b-3p and microRNA-200b-5p in the inhibition of epithelial-to-mesenchymal transition in triple-negative breast cancer. Oncotarget. 2015; 6(18):16638-52. PMC: 4599295. DOI: 10.18632/oncotarget.3184. View

Qiao Y, Shiue C, Zhu J, Zhuang T, Jonsson P, Wright A . AP-1-mediated chromatin looping regulates ZEB2 transcription: new insights into TNFα-induced epithelial-mesenchymal transition in triple-negative breast cancer. Oncotarget. 2015; 6(10):7804-14. PMC: 4480717. DOI: 10.18632/oncotarget.3158. View

Zhang H, Xu L, Li E . A family of pleiotropically acting microRNAs in cancer progression, miR-200: potential cancer therapeutic targets. Curr Pharm Des. 2013; 20(11):1896-903. DOI: 10.2174/13816128113199990519. View

Agajanian M, Runa F, Kelber J . Identification of a PEAK1/ZEB1 signaling axis during TGFβ/fibronectin-induced EMT in breast cancer. Biochem Biophys Res Commun. 2015; 465(3):606-12. DOI: 10.1016/j.bbrc.2015.08.071. View

Kotiyal S, Bhattacharya S . Breast cancer stem cells, EMT and therapeutic targets. Biochem Biophys Res Commun. 2014; 453(1):112-6. DOI: 10.1016/j.bbrc.2014.09.069. View

Perdigao-Henriques R, Petrocca F, Altschuler G, Thomas M, Le M, Tan S . miR-200 promotes the mesenchymal to epithelial transition by suppressing multiple members of the Zeb2 and Snail1 transcriptional repressor complexes. Oncogene. 2015; 35(2):158-72. DOI: 10.1038/onc.2015.69. View

10.

Zhou M, Liu Z, Zhao Y, Ding Y, Liu H, Xi Y . MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. J Biol Chem. 2010; 285(28):21496-507. PMC: 2898411. DOI: 10.1074/jbc.M109.083337. View

11.

Zhang G, An H, Fang X . MicroRNA-144 regulates proliferation, invasion, and apoptosis of cells in malignant solitary pulmonary nodule via zinc finger E-box-binding homeobox 1. Int J Clin Exp Pathol. 2015; 8(5):5960-7. PMC: 4503199. View

12.

Pan H, Wen Z, Huang Y, Cheng X, Wang G, Zhou Y . Down-regulation of microRNA-144 in air pollution-related lung cancer. Sci Rep. 2015; 5:14331. PMC: 4585805. DOI: 10.1038/srep14331. View

13.

Lan F, Yu H, Hu M, Xia T, Yue X . miR-144-3p exerts anti-tumor effects in glioblastoma by targeting c-Met. J Neurochem. 2015; 135(2):274-86. DOI: 10.1111/jnc.13272. View

14.

Yu L, Yang Y, Hou J, Zhai C, Song Y, Zhang Z . MicroRNA-144 affects radiotherapy sensitivity by promoting proliferation, migration and invasion of breast cancer cells. Oncol Rep. 2015; 34(4):1845-52. DOI: 10.3892/or.2015.4173. View

15.

Jang M, Kim H, Kim E, Chung Y, Park S . Expression of epithelial-mesenchymal transition-related markers in triple-negative breast cancer: ZEB1 as a potential biomarker for poor clinical outcome. Hum Pathol. 2015; 46(9):1267-74. DOI: 10.1016/j.humpath.2015.05.010. View

16.

Shen L, Mitscher L, Sharma P, ODonnell T, Chu D, Cooper C . Mechanism of inhibition of DNA gyrase by quinolone antibacterials: a cooperative drug--DNA binding model. Biochemistry. 1989; 28(9):3886-94. DOI: 10.1021/bi00435a039. View

17.

Luo Y, Wang X, Wang H, Xu Y, Wen Q, Fan S . High Bak Expression Is Associated with a Favorable Prognosis in Breast Cancer and Sensitizes Breast Cancer Cells to Paclitaxel. PLoS One. 2015; 10(9):e0138955. PMC: 4583467. DOI: 10.1371/journal.pone.0138955. View

18.

Si W, Huang W, Zheng Y, Yang Y, Liu X, Shan L . Dysfunction of the Reciprocal Feedback Loop between GATA3- and ZEB2-Nucleated Repression Programs Contributes to Breast Cancer Metastasis. Cancer Cell. 2015; 27(6):822-36. DOI: 10.1016/j.ccell.2015.04.011. View

19.

Guan H, Liang W, Xie Z, Li H, Liu J, Liu L . Down-regulation of miR-144 promotes thyroid cancer cell invasion by targeting ZEB1 and ZEB2. Endocrine. 2014; 48(2):566-74. DOI: 10.1007/s12020-014-0326-7. View

20.

Zhang P, Sun Y, Ma L . ZEB1: at the crossroads of epithelial-mesenchymal transition, metastasis and therapy resistance. Cell Cycle. 2015; 14(4):481-7. PMC: 4614883. DOI: 10.1080/15384101.2015.1006048. View